Which peptides are studied in relation to resting metabolic rate?
A research-supply review of the peptide and peptide-adjacent compounds examined in studies that measure resting metabolic rate, resting energy expenditure, or resting metabolism as an outcome.
The compounds most often studied in relation to resting metabolic rate (RMR) — also reported in the literature as resting energy expenditure (REE) or resting metabolism — are not a single peptide class. They fall into three groups: incretin receptor agonists (semaglutide, tirzepatide), the myostatin-pathway antibody bimagrumab, and the leucine metabolite calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB), usually paired with vitamin D3. Sirtuin-activating bioactive compounds, including nicotinamide riboside, appear in the same research space. RMR is measured in these studies as a secondary or exploratory endpoint, typically by indirect calorimetry, and is most often interpreted alongside body-composition change rather than in isolation.
Identifiers are given only where the evidence block supplies them. Calcium-HMB is the calcium salt of beta-hydroxy-beta-methylbutyrate, a metabolite of the branched-chain amino acid leucine; the trials cited here do not state a sequence, formula, or molecular weight. Bimagrumab is described as an investigational new drug that inhibits the activin type II receptor (ActRII) pathway [4]. Semaglutide and tirzepatide act at the glucagon-like peptide 1 receptor (GLP-1 RA) axis, with tirzepatide described in the evidence as a GLP-1 receptor agonist medication [6]. The mechanistic thread running through this literature is energy expenditure: weight loss itself lowers energy expenditure through fat-free mass loss and through mass-independent hormonal adaptations [10].
Research Studies
Calcium-HMB plus vitamin D3 and resting metabolism in older adults starting semaglutide
A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium-HMB plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants receive the combination or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass by dual-energy X-ray absorptiometry from baseline to month 6; resting metabolic rate is among the secondary assessments, alongside body composition, muscle strength, physical performance, gait, and physical activity [1].
Bimagrumab with a GLP-1 receptor agonist and resting metabolic rate in adults with obesity
In adults with obesity seeking treatment, the stated rationale is that weight loss should ideally consist almost exclusively of fat mass, whereas loss of muscle and bone is an unintentional consequence that may reduce resting metabolic rate and increase fall and fracture risk. Data in animals and humans are cited as suggesting that bimagrumab, which inhibits the activin type II receptor, may maximize fat-mass loss while maintaining muscle mass when combined with a GLP-1 receptor agonist. The trial examines body composition, insulin sensitivity, and bone in this population [4].
Semaglutide or tirzepatide versus structured lifestyle change and resting metabolic rate
One study compares two weight-loss strategies: adults starting a GLP-1 receptor agonist (semaglutide or tirzepatide) prescribed by their own physician, versus adults in a structured program of reduced-calorie diet plus increased physical activity. Both groups complete assessments at baseline and after three months, with weight, body composition, blood pressure, and resting metabolic rate measured at each visit, alongside a blood draw [6].
Sirtuin activators and energy expenditure
The sirtuin family, particularly SIRT1 and SIRT3, is described as a target of interest because of its involvement in mitochondrial biogenesis, energy expenditure, oxidative metabolism, and insulin sensitivity regulation. Bioactive compounds that activate sirtuins, including nicotinamide riboside, are the subject of this work in the context of obesity as a chronic, multifactorial disease and the limited long-term effectiveness of lifestyle-based weight management [3].
GLP-1 receptor agonists and energy expenditure: scoping review findings
A scoping review examined the effects of GLP-1 receptor agonists, as monotherapy and in combination, on energy expenditure. It notes that weight loss reduces energy expenditure through body-composition alterations such as fat-free mass and fat-mass losses, and through mass-independent adaptations including hormonal changes, and that GLP-1 receptor agonists are indicated for obesity management [10].
Resting metabolic rate response to fasting as a phenotyping variable
A prospective, single-center, longitudinal study aims to develop a clinically applicable method of metabolic phenotyping to personalize obesity therapy. The concept is that the way a person's resting metabolic rate responds to a 24-hour fast distinguishes two phenotypes: a "thrifty" metabolism showing a significant RMR drop during fasting, and a "spendthrift" metabolism showing little to no drop, or a slight increase [8].
Energy availability, endocrine signalling and metabolic rate in athletes
Work on energy availability defines it as the balance between daily energy intake and exercise energy expenditure, with low energy availability (LEA) occurring when intake is athletically inadequate. Acute or chronic LEA is reported to suppress the reproductive system, disrupt the menstrual cycle, and produce interrelated endocrine consequences through changes in other hormonal pathways, with relevance across the lifespan from young athletes to older adults attempting weight loss [7].
Mitochondrial and mtDNA release in hyperglycaemia-driven metabolic injury
Research in diabetes reports a mechanism linking chronic hyperglycaemia to systemic metabolic impairment through reactive oxygen species-driven mitochondrial dysfunction and mtDNA release, a pathway described as communicating metabolic stress beyond individual cells [9]. This is a cellular and molecular finding; it does not report resting metabolic rate as an outcome.
Comparison of measured endpoints across the cited studies
| Study population | Compound or intervention | Resting metabolic rate role |
|---|---|---|
| Adults 65–85 with type 2 diabetes newly starting semaglutide [1] | Calcium-HMB plus vitamin D3 vs placebo | Secondary assessment |
| Adults with obesity [4] | Bimagrumab plus GLP-1 receptor agonist | Named as a health consequence of muscle loss |
| Adults starting semaglutide or tirzepatide vs lifestyle program [6] | GLP-1 receptor agonist vs diet and activity | Measured at baseline and 3 months |
| Morbidly obese individuals [8] | 24-hour fast (phenotyping) | Primary discriminator between phenotypes |
Where the evidence is animal-only or in vitro
The bimagrumab rationale explicitly rests on data in animals and humans, and the compound is described as an investigational new drug [4]. The mitochondrial and mtDNA release findings are cellular and molecular work in diabetes [9]. The remaining cited studies are human trials or reviews; none of the evidence supplied here establishes a peptide that raises resting metabolic rate as a standalone effect, and no dose, sequence, or molecular weight is given for any compound in this block.
Sources
- [1] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
- [2] Discovering Determinants of Food Intake by Application of Artificial Intelligence to Complex, High-Dimensional Data
- [3] Sirtuin Activators and Weight Loss
- [4] Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
- [5] Physical Exercise on Metabolic Health, Gut Microbiota, Physical Fitness, and Quality of Life in Obese Breast Cancer Survivors
- [6] Tirzepatide Impact Assessment Study
- [7] Energy Deficiency and Athletic Performance
- [8] Metabolic Phenotyping for Personalized Obesity Therapy
- [9] ROS-driven mitochondrial and mtDNA release as a novel pathway of metabolic injury in diabetes
- [10] Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review
If you are reading this for personal health reasons
The materials described here are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for human use. Anyone considering a compound for themselves should speak to a licensed clinician.